IL27 and neoplasm: Future studies should explore whether IL-27 could overcome immunotherapy resistance in solid tumors with low immunogenicity and highly suppressive T cell hostile TME; however, recent evidence suggests that IL-27 can skew TAM polarization towards an M1-like phenotype4 and it is becoming evident that reshaping TME towards an antitumor milieu is pivotal to promote immunotherapy efficacy.5 However, baseline IL-27 expression predicted immunotherapy response in only a limited number of datasets and tumor types.